About Zybio
Zybio is a company. It operates as a Direct-to-Consumer (D2C) and Reseller / Distribution. The company has 277 employees as of December 31, 2024. Zybio offers products and services including Swine Vaccines, Poultry Vaccines, Cattle and Sheep Vaccines, and Pet Vaccines.
- Employees 277 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
- Legal Name Zhengye Biotechnology Holding Limited
-
Annual Revenue
$25.89 M (USD)-13.32as on Dec 31, 2024
-
Net Profit
$1.57 M (USD)-64.6as on Dec 31, 2024
-
EBITDA
$5.61 M (USD)-49.52as on Dec 31, 2024
-
Latest Funding Round
-
Investors
-
Employee Count
277
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Zybio
Zybio is a publicly listed company on the NASDAQ with ticker symbol ZYBT in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Zybio
Zybio offers a comprehensive portfolio of products and services, including Swine Vaccines, Poultry Vaccines, Cattle and Sheep Vaccines, and Pet Vaccines.
Vaccines for swine are developed to prevent diseases.
Vaccines for poultry are produced to ensure protection.
Vaccines for cattle and sheep prevent specific diseases.
Vaccines for pets are designed for disease prevention.
Funding Insights of Zybio
Investments & Acquisitions by Zybio
Financial Statements - Zybio
Zybio Comparisons
Competitors of Zybio
Frequently Asked Questions about Zybio
As of Dec 31, 2024, the latest employee count at Zybio is 277.
Annual revenue of Zybio is $25.89M as on Dec 31, 2024.
Animal vaccines are manufactured by Zybio, focusing on swine, poultry, cattle, sheep, and pets. Operations are based in Jilin City, China, with 14 GMP production lines. Products are exported to countries like Egypt, Pakistan, and Vietnam. Innovation is emphasized through research centers and laboratories for vaccine development. Recognition as a high-tech enterprise and multiple awards for industry contributions are received. The sector of animal health is primarily served with a focus on quality and technological advancement.
Zybio offers Swine Vaccines, Poultry Vaccines, Cattle and Sheep Vaccines, and Pet Vaccines.
Yes, Zybio is publicly traded on NASDAQ under the ticker symbol ZYBT.
The ticker symbol of Zybio is ZYBT on NASDAQ.